Files and links (1)
Published, Version of Record (VoR)Open Access (License Unspecified), Open
Journal article
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023
MMWR. Morbidity and mortality weekly report, v 72(34), pp 920-925
25 Aug 2023
PMID: 37616235
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Respiratory syncytial virus (RSV) is the leading cause of and Drug Administration approved nirsevimab, a long-acting monoclonal antibody, for passive immunization to prevent RSV-associated lower respiratory tract infection among infants and young children. Since October 2021, the Advisory Committee on Immunization Practices (ACIP) Maternal and Pediatric RSV Work Group has reviewed evidence on the safety and efficacy of nirsevimab among infants and young children. On August 3, 2023, ACIP recommended nirsevimab for all infants aged <8 months who are born during or entering their first RSV season and for infants and children disease and are entering their second RSV season. On the basis of pre-COVID-19 pandemic patterns, nirsevimab could be October through the end of March. Nirsevimab can prevent severe RSV disease among infants and young children at increased risk for severe RSV disease.
Metrics
Details
- Title
- Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023
- Creators
- Jefferson M. Jones - Centers for Disease Control and PreventionKatherine E. Fleming-Dutra - Centers for Disease Control and PreventionMila M. Prill - Centers for Disease Control and PreventionLauren E. Roper - Centers for Disease Control and PreventionOliver Brooks - Watts Health CenterPablo J. Sanchez - The Ohio State UniversityCamille N. Kotton - Harvard UniversityBarbara E. Mahon - Centers for Disease Control and PreventionSarah Meyer - Centers for Disease Control and PreventionSarah S. Long - Drexel University, PediatricsMeredith L. Mcmorrow - Centers for Disease Control and Prevention
- Publication Details
- MMWR. Morbidity and mortality weekly report, v 72(34), pp 920-925
- Publisher
- CENTERS DISEASE CONTROL & PREVENTION; ATLANTA
- Number of pages
- 6
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:001060586500001
- Scopus ID
- 2-s2.0-85168715812
- Other Identifier
- 991021861193504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
Highly Cited Paper
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Public, Environmental & Occupational Health